MedPath

INMUNOVA S.A.

🇦🇷Argentina
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

6

Active:0
Completed:4

Trial Phases

3 Phases

Phase 1:1
Phase 2:3
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (60.0%)
Phase 1
1 (20.0%)
Phase 3
1 (20.0%)

Efficacy of INM004 in Children With STEC-HUS

Phase 3
Recruiting
Conditions
Hemolytic-Uremic Syndrome
Interventions
Other: Placebo
First Posted Date
2024-04-29
Last Posted Date
2025-02-25
Lead Sponsor
Inmunova S.A.
Target Recruit Count
220
Registration Number
NCT06389474
Locations
🇦🇷

Hospital Interzonal Dr. José Penna, Bahia Blanca, Buenos Aires, Argentina

🇦🇷

Hospital de niños Sor María Ludovica, La Plata, Buenos Aires, Argentina

🇦🇷

Clinica del niño y la madre, Mar Del Plata, Buenos Aires, Argentina

and more 34 locations

A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS

Phase 2
Completed
Conditions
Pediatric Kidney Disease
Hemolytic-Uremic Syndrome
Diarrhea-Associated Hemolytic Uremic Syndrome
Interventions
Other: SoC
First Posted Date
2022-10-06
Last Posted Date
2023-08-21
Lead Sponsor
Inmunova S.A.
Target Recruit Count
57
Registration Number
NCT05569746
Locations
🇦🇷

Hospital Interzonal Dr. José Penna, Bahía Blanca, Buenos Aires, Argentina

🇦🇷

Hospital El Cruce - Néstor Kirchner, Florencio Varela, Buenos Aires, Argentina

🇦🇷

Hospital De Niños Sor María Ludovica, La Plata, Buenos Aires, Argentina

and more 13 locations

Effectiveness and Safety Study of Specific Hyperimmune Equine Serum for the Treatment of Severe Hospitalized SARS-CoV-2 in Adults: Retrospective Cohort Study

Completed
Conditions
Covid19
First Posted Date
2021-07-08
Last Posted Date
2022-04-06
Lead Sponsor
Inmunova S.A.
Target Recruit Count
847
Registration Number
NCT04954235
Locations
🇦🇷

Hospital de Campaña "Escuela Hogar", Corrientes, Argentina

A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.

Phase 2
Completed
Conditions
Covid19
Interventions
Drug: Placebo
First Posted Date
2020-07-31
Last Posted Date
2021-02-11
Lead Sponsor
Inmunova S.A.
Target Recruit Count
242
Registration Number
NCT04494984
Locations
🇦🇷

Hospital de Cuenca Alta, Cañuelas, Buenos Aires, Argentina

🇦🇷

Hospital Alta Complejidad "El Cruce" Dr. Néstor Carlos Kirchner, Florencio Varela, Buenos Aires, Argentina

🇦🇷

Hospital Prof. Dr. Bernardo A. Houssay, Florida, Buenos Aires, Argentina

and more 20 locations

Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS

Phase 2
Terminated
Conditions
STEC, Unspecified
Hemolytic-Uremic Syndrome
Bloody Diarrhea
Pediatric Kidney Disease
Interventions
Drug: Placebo
First Posted Date
2019-10-18
Last Posted Date
2023-07-19
Lead Sponsor
Inmunova S.A.
Target Recruit Count
11
Registration Number
NCT04132375
Locations
🇦🇷

Hospital Penna, Bahia Blanca, Buenos Aires, Argentina

🇦🇷

Hospital Sor Maria Ludovica, La Plata, Buenos Aires, Argentina

🇦🇷

Hospital Lucio Molas, Santa Rosa, LA Pampa, Argentina

and more 4 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath